Abstract | BACKGROUND: METHODS: Fifty-four heavy smokers (mean 33.1 cigarettes per day for 24 years) were randomly prescribed 30 mg/d of buspirone or placebo beginning 3 weeks before abrupt smoking cessation. Validated nicotine withdrawal and anxiety scales were administered at baseline and serially for 2 weeks after cessation. RESULTS: Baseline demographic and nicotine-dependence measures were similar for each group. Three smokers (1 on buspirone, 2 on placebo) dropped out of the protocol prior to the quit date. Both groups had significant withdrawal effects over time (analysis of variance [ANOVA] P = 0.0001). There was a significant buspirone effect on any nicotine withdrawal symptoms (ANOVA, alpha = 0.05). Smokers who relapsed, regardless of group, reported significantly worse craving, irritability, anxiety, and difficulty concentrating than abstainers (P less than 0.05). Relapse rates at follow-up visits were not significantly different between groups. Two-week abstinence rates were 52 percent for placebo and 62 percent for buspirone (chi-square, P = 0.760). CONCLUSIONS:
|
Authors | M D Robinson, Y L Pettice, W A Smith, E A Cederstrom, D E Sutherland, H Davis |
Journal | The Journal of the American Board of Family Practice
(J Am Board Fam Pract)
1992 Jan-Feb
Vol. 5
Issue 1
Pg. 1-9
ISSN: 0893-8652 [Print] United States |
PMID | 1561909
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Analysis of Variance
- Buspirone
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Nicotine
(adverse effects)
- Prospective Studies
- Substance Withdrawal Syndrome
(drug therapy)
- Time Factors
|